Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 May;41(5):1349-1357.
doi: 10.1007/s10067-021-05980-5. Epub 2021 Nov 16.

Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus

Ernesto Zavala-Flores  1   2 , Jannin Salcedo-Matienzo  3   4 , Ana Quiroz-Alva  3   4 , Alfredo Berrocal-Kasay  3   4
Affiliations
Observational Study

Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus

Ernesto Zavala-Flores et al. Clin Rheumatol. 2022 May.

Abstract

The objective of this study is to identify post SARS-CoV-2 vaccine BNT162b2 (BioNTech & Pfizer) side effects in patients with systemic lupus erythematosus (SLE) at the Cayetano Heredia Hospital, Lima, Peru. A descriptive observational study was designed in patients with SLE at the Immuno-Rheumatology Department of the Cayetano Heredia Hospital, Lima, Peru, immunized with the BNT162b2 vaccine from May 21 to June 30, 2021. Of the total number of patients seen in the service, 100 received the vaccine's 1st dose, and 90 patients received the 2nd dose; 90% and 92.2% presented symptoms within 10 days after immunization (1st and 2nd doses, respectively), being pain at the inoculation site the most frequent (87%); most of the symptoms presented were of mild intensity. There were 27 episodes of post-immunization flare, 9% and 20% after the 1st and 2nd doses, respectively; the predominant type of flare was articular (85.1%), followed by dermal (18.5%). It was found that a history of renal involvement was associated with the risk of developing flare RR 0.38 (0.15-0.91) and the use of hydroxychloroquine and azathioprine prior to immunization 0.20 (0.06-0.63) and 7.96 (2.70-23.43) respectively. In 100 SLE patients immunized with BNT162b2 vaccine against SARS-CoV-2, 27% of SLE reactivation episodes occurred, two patients were hospitalized for flare severity, and none died. Key Points • Up to 92.2% presented some type of symptom after vaccination, being mostly local and of mild intensity. • Of the population studied, there were 27 episodes of post-vaccination flare, most of which were mild. • In the studied population, taking hydroxychloroquine and having a history of renal disease were associated with a lower risk of presenting post-vaccination flare.

Keywords: (MeSH NLM): Coronavirus; Autoimmune diseases; COVID-19; Systemic lupus erythematosus; Vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Symptoms presented in patients with lupus after the 1st and 2nd doses of immunization against SARS-CoV-2
Fig. 2
Fig. 2
Flow chart
See this image and copyright information in PMC

References

    1. McGill COVID-19 Vaccine Tracker Team. COVID19 vaccine tracker. https://covid19.trackvaccines.org/vaccines/ Date Accessed 15 Aug 2021
    1. Boekel L, Hooijberg F, van Kempen ZLE, Vogelzang EH, Tas SW, Killestein J, et al. Perspective of patients with autoimmune diseases on COVID-19 vaccination. Lancet Rheumatol. 2021;3(4):241–e243. doi: 10.1016/S2665-9913(21)00037-0. - DOI - PMC - PubMed
    1. Felten R, Dubois M, Ugarte-Gil MF, Chaudier A, Kawka L, Bergier H, et al. Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases. Lancet Rheumatol. 2021;3(4):243–e245. doi: 10.1016/S2665-9913(21)00039-4. - DOI - PMC - PubMed
    1. Moutsopoulos HM. A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine. J Autoimmun. 2021;121:102649. doi: 10.1016/j.jaut.2021.102649. - DOI - PMC - PubMed
    1. Connolly CM, Ruddy JA, Boyarsky BJ, Avery RK, Werbel WA, Segev DL et al (2021) Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 10.1136/annrheumdis-2021-220231 - PubMed

Publication types

MeSH terms